Previous 10 | Next 10 |
Puma Biotechnology ( PBYI -3.2% ) slips on below-average in apparent response to results from a Phase 3 clinical trial evaluating Merck's Keytruda (pembrolizumab) for the treatment of triple-negative breast cancer (TNBC) in an adjuvant setting. More news on: Puma Biotechnology, Inc., H...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 8, 2019 following release of its second quarter 2019 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-2...
Health Canada approves Puma Biotechnology's (NASDAQ: PBYI ) NERLYNX (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer within one year after completion of adjuvant therapy with Roche's Herceptin (t...
Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved Health Canada indication ...
MONTREAL, July 16, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) for the extended adjuvant treatment of women with early-stage hormone rec...
Puma Biotechnology ( PBYI -2.6% ) slips on below-average on the heels of preliminary results from a Phase 2 basket study, SUMMIT , evaluating neratinib in HER2-positive cancers. The data were presented at the ESMO World Congress on Gastrointestinal Cancer in Barcelona. More news on: P...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated interim results from the biliary cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, at the European Society for Medical Oncology (ESMO) 2...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cance...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cance...
Puma Biotechnology ( PBYI ) has been a very volatile biotech stock in the last several years: Data by YCharts Last year, we published two articles about Puma with expected growth in the company's stock, Puma Biotechnology: Risky Investment and Puma Biotechnology: Increasing Our Ex...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...